PacBio Q2 Loss Wider Than Expected, Revenue Misses; Guides 2026 Revenue Below Street
PACB is trading near its 52-week low of $1.09 (15% above the low).
Summary
PacBio's Q2 revenue fell to $39M, missing the $40.07M consensus, while adjusted loss per share of $0.14 was a penny worse than expected. Gross margin compressed to 36% on higher compute costs and lower Revio ASPs from strategic multi-system placements. The company guided full-year 2026 revenue to $155M-$165M, well below the $180M+ Street was modeling. This follows today's earlier announcement of a CEO change and a $30M-$40M cost restructuring—the earnings miss and weak guide add urgency to that turnaround. With shares at $1.25 and a $404M market cap, the revenue trajectory and margin pressure raise serious questions about the Vega/SPRQ-Nx ramp delivering the promised second-half inflection.
At the time of this announcement, PACB was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $403.8M. The 52-week trading range was $1.09 to $2.73. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.